D+R受体中CMV预防的肾脏移植预先治疗或预防疗法 (KPoP)
D+R-受体预防CMV的肾脏移植预先治疗或预防疗法(KPOP)
This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily [both dose adjusted per Food and Drug Administration (FDA) label] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study.
Estimated Time to Complete Enrollment: 4 years
研究概览
地位
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Megan Gish
- 电话号码:415-476-1985
- 邮箱:megan.gish@ucsf.edu
学习地点
-
-
California
-
San Francisco、California、美国、94117
- 招聘中
- University of California, San Francisco School of Medicine
-
接触:
- Puneet Sood, MD, MPH
- 电话号码:415-353-1551
- 邮箱:puneet.sood@ucsf.edu
-
-
Florida
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami Miller School of Medicine
-
接触:
- Yoichiro Natori, MD
- 电话号码:305-355-5418
- 邮箱:yxn138@med.miami.edu
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University School of Medicine
-
接触:
- Aneesh Mehta, MD
- 电话号码:(404) 727-8435
- 邮箱:aneesh.mehta@emory.edu
-
-
Nebraska
-
Omaha、Nebraska、美国、68198
- 尚未招聘
- University of Nebraska Medical Center
-
接触:
- Sias Scherger, MD
- 电话号码:402-559-4000
- 邮箱:sscherger@unmc.edu
-
首席研究员:
- Sias Scherger, MD
-
-
New Jersey
-
Livingston、New Jersey、美国、07039
- 招聘中
- Robert Wood Johnson Health Network Barnabas Health
-
接触:
- Francis Weng, MD
- 电话号码:(973) 322-5065
- 邮箱:francis.weng@rwjbh.org
-
-
North Carolina
-
Durham、North Carolina、美国、27708
- 招聘中
- Duke University
-
接触:
- Scott Sanoff, MD
- 电话号码:919-620-5300
- 邮箱:Scott.sanoff@duke.edu
-
首席研究员:
- Scott Sanoff, MD
-
-
Texas
-
Dallas、Texas、美国、75390
- 尚未招聘
- University of Texas Southwestern
-
接触:
- Ricardo La Hoz, MD
- 电话号码:214-645-6427
- 邮箱:ricardo.lahoz@utsouthwestern.edu
-
首席研究员:
- Ricardo La Hoz, MD
-
-
Virginia
-
Richmond、Virginia、美国、23219
- 招聘中
- Medical College of Virginia Commonwealth
-
接触:
- Guarav Gupta, MD
- 电话号码:804-828-4104
- 邮箱:gaurav.gupta@vcuhealth.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Subject has provided written informed consent.
-
Age ≥ 18 years of age at the time of informed consent.
-
Negative for IgG antibody to CMV as assessed in a CLIA-certified laboratory between 28 days prior to transplant and up to 10 days post-transplant but prior to randomization.
-
Received a kidney transplant from a CMV seropositive (IgG positive) donor in the past 10 days prior to enrollment
-
Individuals of reproductive (childbearing) potential must have a negative pregnancy test (serum or urine) collected prior to randomization (SOC results within 7 days prior to transplant may be used), and must also agree to use a medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence from the time of enrollment through until discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.
NOTE: Individuals of reproductive potential are defined as individuals who have reached menarche and who have not been post-menopausal for at least 12 consecutive months with follicle stimulating hormone (FSH) ≥40 IU/mL or 24 consecutive months if an FSH is not available, i.e., who have had menses within the preceding 24 months, and have not undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, or salpingectomy).
-
If male, must agree to practice a barrier method of contraception or abstinence from the time of enrollment through 3 months after discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.
Exclusion Criteria:
-
In the opinion of the investigator, participants who are unable or unwilling to undergo preemptive therapy protocol (weekly CMV PCR, etc.)
-
Patients who are breastfeeding or planning to breastfeed within 6 months post-transplant
-
Allergy to valganciclovir/ganciclovir or Letermovir
-
Receipt of immunoglobulin or CMV-specific immunoglobulin within the last 3 months prior to the qualifying CMV IgG serology as described in inclusion criteria #3 (this includes COVID convalescent plasma)
-
Currently enrolled or anticipated enrollment in another interventional study that, in the opinion of scientific leadership team, could affect evaluation of the primary safety and/or efficacy outcomes.
-
Most recent platelet count post-transplant <25,000/uL
-
Most recent ANC performed post-transplant <1000/uL
-
Multi-organ transplant (except simultaneous kidney-pancreas) within the past 7 days
-
Prior or planned receipt of a hematopoietic cell transplant
-
Baseline immunodeficiency prior to transplant, including but not limited to:
- Known or suspected HIV infection
- Congenital or acquired immunodeficiency
-
Unacceptable immunosuppression
- Receipt of desensitization therapy prior to kidney transplant, or
- Receipt of an ABO-incompatible kidney transplant except A2 to blood type B
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pre-emptive Therapy
900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. |
Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks. |
|
有源比较器:Prophylaxis
900 mg of Valganciclovir given orally once daily to subjects for 200 days post transplantation. All dosages adjusted for renal dysfunction. |
Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 200 days post transplantation as prophylaxis. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
终点委员会(EC)确认的CMV疾病(综合征或最终器官)的发生率是移植后的1年。
大体时间:移植后的1年内
|
移植后的1年内
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
研究人员确定的CMV疾病的比例
大体时间:到移植后1年
|
到移植后1年
|
|
|
活检预先排斥(Bipar)的天数(BIPAR)
大体时间:从随机分配日期到任何原因的双乳头日期,最多可评估5.5年
|
从随机分配日期到任何原因的双乳头日期,最多可评估5.5年
|
|
|
嫁接损失的天数
大体时间:从随机分组的日期到任何原因的移植日期损失日期,最高为5.5岁
|
从随机分组的日期到任何原因的移植日期损失日期,最高为5.5岁
|
|
|
死亡的时间
大体时间:从随机日期到任何原因的死亡日期,最多可评估5.5岁
|
从随机日期到任何原因的死亡日期,最多可评估5.5岁
|
|
|
移植后1、2、3和4年,ML/min/1.73m2的平均估计肾小球滤过率(EGFR)
大体时间:移植后的1、2、3和4年
|
移植后的1、2、3和4年
|
|
|
Non-inferiority of PET (within a 10% margin) vs AP for EC-confirmed CMV disease by 1-year post-transplant, contingent on failure to meet the primary superiority endpoint.
大体时间:by 1-year post-transplant
|
Although the study sample size is powered to detect the superiority of one preventive strategy compared to the other, it is possible that the two approaches may have similar efficacy with respect to prevention of CMV disease. Therefore, should there be insufficient evidence to conclude superiority of one of the approaches, a key Secondary Outcome is a non-inferiority assessment of preemptive therapy to prophylaxis, assuming a non-inferiority margin of 10%. This margin is based on what is known about the effectiveness of the two approaches as published in literature and the potential that the two strategies could be similarly efficacious in preventing CMV disease. The success rate for the prophylaxis group is estimated to be ~80% based on a systematic review and meta-analysis with hypothesized success rates for the preemptive group expected to be higher. |
by 1-year post-transplant
|
合作者和调查者
调查人员
- 首席研究员:Abhijit P. Limaye, MD、University of California, San Francisco
出版物和有用的链接
一般刊物
- Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A; The Transplantation Society International CMV Consensus Group. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018 Jun;102(6):900-931. doi: 10.1097/TP.0000000000002191.
- Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023 Jul 3;330(1):33-42. doi: 10.1001/jama.2023.9106.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- STUDY00020695
- 1R01AI184205-01 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.